Third Rock shrinks another biotech as Cedilla restructures, CEO and CBO depart
Biotech incubator and investor Third Rock Ventures has pruned another one of its offshoots by replacing the CEO, restructuring and looking for partners for lead assets.
Cedilla Therapeutics, launched in 2018 with $56 million from the VC firm, is “engaged in several strategic discussions related to its lead programs,” a Third Rock spokesperson told Endpoints News via email. Partner Neil Exter, a 16-year veteran of the investment shop, has replaced Alexandra Glucksmann as CEO.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.